TY  - JOUR
AU  - Tan, Aaron C
AU  - Bagley, Stephen J
AU  - Wen, Patrick Y
AU  - Lim, Michael
AU  - Platten, Michael
AU  - Colman, Howard
AU  - Ashley, David M
AU  - Wick, Wolfgang
AU  - Chang, Susan M
AU  - Galanis, Evanthia
AU  - Mansouri, Alireza
AU  - Khagi, Simon
AU  - Mehta, Minesh P
AU  - Heimberger, Amy B
AU  - Puduvalli, Vinay K
AU  - Reardon, David A
AU  - Sahebjam, Solmaz
AU  - Simes, John
AU  - Antonia, Scott J
AU  - Berry, Don
AU  - Khasraw, Mustafa
TI  - Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 9
IS  - 7
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2021-01518
SP  - e002459
PY  - 2021
AB  - With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel-novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the most difficult questions in medical research. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review of trials of novel-novel combination therapies involving immunotherapies or molecular targeted therapies in advanced solid tumors. A MEDLINE search was conducted using a modified Cochrane Highly Sensitive Search Strategy for published clinical trials between July 1, 2017, and June 30, 2020, in the top-ranked medical and oncology journals. Trials were evaluated according to a criterion adapted from previously published Food and Drug Administration guidance and other key considerations in designing trials of combinations. This included the presence of a strong biological rationale, the use of a new established or emerging predictive biomarker prospectively incorporated into the clinical trial design, appropriate comparator arms of monotherapy or supportive external data sources and a primary endpoint demonstrating a clinically meaningful benefit. Of 32 identified trials, there were 11 (34
KW  - clinical trials as topic (Other)
KW  - combination (Other)
KW  - drug therapy (Other)
KW  - immunotherapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34215688
DO  - DOI:10.1136/jitc-2021-002459
UR  - https://inrepo02.dkfz.de/record/169711
ER  -